In our study, we developed a GC panel incorporating TCGA and ACRG classification: EBV ISH for EBV-positivity, MMR protein (MLH1, PMS2, MSH2, and MSH6) for MSI tumors, druggable RTKs (HER2, EGFR, MET), PI3K pathway component (PTEN), and p53 protein. This evidence concerns the gene PMS2 and gastric cancer.